Adagene INC

Ulf Grawunder, a Director of Adagene Inc., received 20,000 shares of common stock on August 13, 2026.

Peter Luo, Chief Executive Officer and a Director of Adagene Inc., purchased 23,245 shares of common stock on August 6, 2026.

Adagene Inc. reports an update on beneficial ownership, with Peter Luo and HAN 2020 Irrevocable Trust holding significant stakes and exercising voting power.

Adagene, Inc. CEO Peter Luo and related entities have updated their beneficial ownership, including significant transfers of shares to the HAN 2020 Irrevocable Trust for estate planning purposes and a change in the trust's independent trustee.

WuXi PharmaTech Healthcare Fund I L.P. and WuXi AppTec Co., Ltd. have updated their Schedule 13G filing regarding their beneficial ownership of Adagene Inc. ordinary shares.

Janus Henderson Group plc has reported beneficial ownership of 10.1% of Adagene Inc.'s American Depository Receipts, holding 6,666,666 shares.

Jorey Chernett has reported a 5.1% beneficial ownership stake in Adagene Inc.'s ordinary shares, as detailed in a recent Schedule 13G filing.

Vincent C. Smith and affiliated entities have reported an aggregate beneficial ownership of 8.7% of Adagene Inc.'s Ordinary Shares.

WuXi PharmaTech Healthcare Fund I L.P. and WuXi AppTec Co., Ltd. have disclosed a 7.0% beneficial ownership stake in Adagene Inc. as of September 30, 2025.

Panacea Venture Healthcare Fund II and related entities have filed an Amendment No. 3 to their Schedule 13G, disclosing a 3.8% beneficial ownership in Adagene Inc. as of September 30, 2025.